Kidney Cancer

Cell fusion vaccine approach being tested

Published in Vaccine Weekly, December 11th, 2002

Genzyme Molecular Oncology (GZMO) launched a new clinical trial in kidney cancer that uses an innovative vaccine made from combining the patient's own cancer cells with powerful, immune-stimulating cells to fight the devastating disease.

Genzyme Molecular Oncology, a division of Genzyme Corporation, is the first commercial entity in the United States to pursue development of patient-specific cancer vaccines produced using this electrical fusion approach.

The phase I/II kidney cancer trial is now enrolling patients in Boston at the Beth Israel Deaconess Medical Center. Enrollment also is expected to begin shortly at the Dana-Farber Cancer Institute. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry